Skip to Content

Bosentan Pregnancy and Breastfeeding Warnings

Bosentan is also known as: Tracleer

Bosentan Pregnancy Warnings

Bosentan has been assigned to pregnancy category X by the FDA. Bosentan is expected to cause fetal harm if administered to pregnant women. Animal data have revealed teratogenicity including malformations of the head, mouth, face and large blood vessels in addition to an increased number of stillbirths and increased mortality. There are no data on the use of bosentan in human pregnancy. Bosentan is considered contraindicated for use in pregnancy. Prior to initiating therapy, pregnancy must be excluded and prevented during treatment with a reliable form of contraception. It is important to note that hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives may not be reliable in the presence of bosentan and should not be used as the sole contraceptive method in patients receiving bosentan. Follow-up urine or serum pregnancy tests should be obtained monthly in women of childbearing potential. The patient should be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy, she must notify the physician immediately for pregnancy testing. If the pregnancy test is positive, the physician and patient must discuss the risk to the pregnancy and to the fetus.

An open-label, single arm, multicenter, safety study evaluated the effect on testicular function of bosentan. Based on these findings and preclinical data from endothelin receptor antagonists, it cannot be excluded that endothelin receptor antagonists such as bosentan have an adverse effect on spermatogenesis.

See references

Bosentan Breastfeeding Warnings

There are no data on the excretion of bosentan into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. Kenyon KW, Nappi JM "Bosentan for the treatment of pulmonary arterial hypertension." Ann Pharmacother 37 (2003): 1055-62
  2. "Product Information. Tracleer (bosentan)." Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.

References for breastfeeding information

  1. "Product Information. Tracleer (bosentan)." Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.